A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

被引：2
|
作者：
Chen, Jiaying
Ji, Qinghai
Cao, Junning
Ji, Dongmei
Bai, Chunmei
Lin, Yansong
Pan, Bin
Sun, Guofang
Li, Jing
Qi, Chuan
Hua, Ye
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Phase Unit, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
    Cabanillas, Maria E.
    de Souza, Jonas A.
    Geyer, Susan
    Wirth, Lori J.
    Menefee, Michael E.
    Liu, Stephen V.
    Shah, Komal
    Wright, John
    Shah, Manisha H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3315 - +
  • [22] Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
    Hewett, Yvonne
    Ghimire, Subash
    Farooqi, Bilal
    Shah, Binay K.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (01) : 28 - 32
  • [23] Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
    Haugen, Bryan
    French, Jena
    Worden, Francis P.
    Konda, Bhavana
    Sherman, Eric Jeffrey
    Dadu, Ramona
    Gianoukakis, Andrew G.
    Wolfe, Eric G.
    Foster, Nathan R.
    Bowles, Daniel W.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
    Tumino, Dario
    Frasca, Francesco
    Newbold, Kate
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [25] MATCHING-ADJUSTED INDIREC TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC)
    Tremblay, G.
    Holbrook, T.
    Milligan, G.
    Pelletier, C.
    VALUE IN HEALTH, 2015, 18 (03) : A11 - A11
  • [26] Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer
    Lin, Yan-Song
    Zhang, Xin
    Wang, Chen
    Liu, Yan-Qing
    Guan, Wen-Min
    Liang, Jun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (08): : E3027 - E3036
  • [27] Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
    Haugen, B.
    French, J. D.
    Worden, F.
    Konda, B.
    Sherman, E. J.
    Dadu, R.
    Gianoukakis, A. G.
    Mccue, S.
    Foster, N.
    Bowles, D. W.
    Wirth, L. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1086 - S1087
  • [28] Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
    Wadsley, Jon
    Ainsworth, Gemma
    Coulson, Amy Beth
    Garcez, Kate
    Moss, Laura
    Newbold, Kate
    Farnell, Kate
    Swain, Jayne
    Howard, Helen
    Beasley, Matthew
    Weaver, Andrew
    Wood, Katie
    Marshall, Jennifer
    Griffin, Matthew
    Pascoe, Abigail
    Du, Yong
    Taprogge, Jan
    Flux, Glenn
    Brown, Sarah
    THYROID, 2023, 33 (09) : 1119 - 1123
  • [29] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Zohreh Maghsoomi
    Zahra Emami
    Ramin Malboosbaf
    Mojtaba Malek
    Mohammad E. Khamseh
    BMC Cancer, 21
  • [30] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
12345